Medicare Drug Price Explanations Shed Some Light on Future Talks

The Biden administration’s justification of the first cycle of Medicare drug price negotiations is fueling curiosity and uncertainty about a process largely held behind closed doors, just as another round of talks begin in the coming weeks under a new administration.

The Centers for Medicare & Medicaid Services released 10 highly anticipated explanations about its process for determining offers and counteroffers in its landmark Inflation Reduction Act program to set the prices of some of the most expensive and widely used drugs covered under Medicare.

The CMS was required by March 1 to publish explanations about how it determined the ...